Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were down 8.3% during trading on Thursday . The company traded as low as C$0.11 and last traded at C$0.11. Approximately 240,655 shares traded hands during trading, an increase of 150% from the average daily volume of 96,162 shares. The stock had previously closed at C$0.12.
Hemostemix Price Performance
The company’s 50-day simple moving average is C$0.08 and its two-hundred day simple moving average is C$0.07. The firm has a market capitalization of C$10.89 million, a P/E ratio of -6.25 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How to buy stock: A step-by-step guide for beginners
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- How to Start Investing in Real Estate
- Nebius Group: The Rising Star in AI Infrastructure
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
